[
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Mixed Late Afternoon",
    "summary": "Health care stocks were mixed late Thursday afternoon with the NYSE Health Care Index adding 0.1% an",
    "url": "https://finnhub.io/api/news?id=37eac18ea42409c92a18bb44a1de280b1dd229a7477a346d410a8f74f7b451db",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755806697,
      "headline": "Sector Update: Health Care Stocks Mixed Late Afternoon",
      "id": 136470396,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "Health care stocks were mixed late Thursday afternoon with the NYSE Health Care Index adding 0.1% an",
      "url": "https://finnhub.io/api/news?id=37eac18ea42409c92a18bb44a1de280b1dd229a7477a346d410a8f74f7b451db"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Topples On A Surprise Setback For Its 99.9% Effective HIV Drug",
    "summary": "Gilead Topples On A Surprise Setback For Its 99.9% Effective HIV Drug",
    "url": "https://finnhub.io/api/news?id=a3824295118beddb2506986ed766c1505579d6561875e9d98d515969b873db0e",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755795363,
      "headline": "Gilead Topples On A Surprise Setback For Its 99.9% Effective HIV Drug",
      "id": 136490489,
      "image": "",
      "related": "CVS",
      "source": "DowJones",
      "summary": "Gilead Topples On A Surprise Setback For Its 99.9% Effective HIV Drug",
      "url": "https://finnhub.io/api/news?id=a3824295118beddb2506986ed766c1505579d6561875e9d98d515969b873db0e"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying.",
    "summary": "The injection, called Yeztugo, is highly effective, but its list price is $28, 218 a year in the U.S.",
    "url": "https://finnhub.io/api/news?id=be6a70a6aff1c7fca4c0c3fb825b8b94f57db0bf9674ca31f395fafb6eb7f470",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755792900,
      "headline": "Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying.",
      "id": 136471519,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "The injection, called Yeztugo, is highly effective, but its list price is $28, 218 a year in the U.S.",
      "url": "https://finnhub.io/api/news?id=be6a70a6aff1c7fca4c0c3fb825b8b94f57db0bf9674ca31f395fafb6eb7f470"
    }
  },
  {
    "ts": null,
    "headline": "Why Gilead Sciences (GILD) Shares Are Sliding Today",
    "summary": "Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) fell 3.5% in the morning session after reports that CVS Health will not be adding the company's new HIV prevention drug, Yeztugo, to its commercial insurance plans for now.",
    "url": "https://finnhub.io/api/news?id=cda0f070c6860ef709e1baabc1cbb555aea5d510916bab4ac6e9f2959c5ab48d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755789361,
      "headline": "Why Gilead Sciences (GILD) Shares Are Sliding Today",
      "id": 136467834,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) fell 3.5% in the morning session after reports that CVS Health will not be adding the company's new HIV prevention drug, Yeztugo, to its commercial insurance plans for now.",
      "url": "https://finnhub.io/api/news?id=cda0f070c6860ef709e1baabc1cbb555aea5d510916bab4ac6e9f2959c5ab48d"
    }
  },
  {
    "ts": null,
    "headline": "Is This the Right Time to Consider Healthcare ETFs?",
    "summary": "XLV lags SPY by double digits over the past year, but Buffett's UNH bet, hedge fund buys and AI optimism hint at a healthcare revival.",
    "url": "https://finnhub.io/api/news?id=6ea5184fc7534f60aa5f43a659c2d6e7645682cc34059adfdfdb6ffb1ee2f1ee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755788400,
      "headline": "Is This the Right Time to Consider Healthcare ETFs?",
      "id": 136467651,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "XLV lags SPY by double digits over the past year, but Buffett's UNH bet, hedge fund buys and AI optimism hint at a healthcare revival.",
      "url": "https://finnhub.io/api/news?id=6ea5184fc7534f60aa5f43a659c2d6e7645682cc34059adfdfdb6ffb1ee2f1ee"
    }
  },
  {
    "ts": null,
    "headline": "4 Value Stocks Every Investor Should Hold in Volatile Times",
    "summary": "StoneCo, CVS, Integer Holdings and USANA emerge as attractive value stocks with low cash-flow ratios and solid growth outlooks.",
    "url": "https://finnhub.io/api/news?id=18d6b5e6c3cf8ba78722e6ada4f4bc990e62f5808d67784bd0ac0d0fe37a7ab1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755787140,
      "headline": "4 Value Stocks Every Investor Should Hold in Volatile Times",
      "id": 136467950,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "StoneCo, CVS, Integer Holdings and USANA emerge as attractive value stocks with low cash-flow ratios and solid growth outlooks.",
      "url": "https://finnhub.io/api/news?id=18d6b5e6c3cf8ba78722e6ada4f4bc990e62f5808d67784bd0ac0d0fe37a7ab1"
    }
  },
  {
    "ts": null,
    "headline": "Update: Market Chatter: CVS Health Won't Cover Gilead's New HIV Prevention Drug Yet",
    "summary": "(Update to add Gilead's comment in the fourth paragraph) CVS Health (CVS) has decided not to incl",
    "url": "https://finnhub.io/api/news?id=4bc881779c3de61e9ec0223c99188902d719f2054e596f1329f340b0e310734c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755782468,
      "headline": "Update: Market Chatter: CVS Health Won't Cover Gilead's New HIV Prevention Drug Yet",
      "id": 136467654,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "(Update to add Gilead's comment in the fourth paragraph) CVS Health (CVS) has decided not to incl",
      "url": "https://finnhub.io/api/news?id=4bc881779c3de61e9ec0223c99188902d719f2054e596f1329f340b0e310734c"
    }
  },
  {
    "ts": null,
    "headline": "Value Investing: 5 Undervalued Stocks Worth Adding to Your Portfolio",
    "summary": "StoneCo, CVS Health, KT, KB Financial and USANA Health stand out as undervalued picks with low P/B ratios and solid growth prospects.",
    "url": "https://finnhub.io/api/news?id=53abbbaf9d6639e507e60b5efeebd270420942ae35f6d48617f05439061fb340",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755782400,
      "headline": "Value Investing: 5 Undervalued Stocks Worth Adding to Your Portfolio",
      "id": 136467953,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "StoneCo, CVS Health, KT, KB Financial and USANA Health stand out as undervalued picks with low P/B ratios and solid growth prospects.",
      "url": "https://finnhub.io/api/news?id=53abbbaf9d6639e507e60b5efeebd270420942ae35f6d48617f05439061fb340"
    }
  },
  {
    "ts": null,
    "headline": "Gilead stock falls after CVS holds off adding HIV prevention shot to plans",
    "summary": "Investing.com -- Gilead Sciences (NASDAQ:GILD) stock fell 2.7% in pre-market trading Thursday after reports that CVS Health (NYSE:CVS) will not add the company’s new HIV prevention drug, Yeztugo, to its commercial plans for now.",
    "url": "https://finnhub.io/api/news?id=a116c6757a9c3aed11072c0198bee501deecfdc663cc8314e3efd6f55e4e2c3e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755780602,
      "headline": "Gilead stock falls after CVS holds off adding HIV prevention shot to plans",
      "id": 136467838,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "Investing.com -- Gilead Sciences (NASDAQ:GILD) stock fell 2.7% in pre-market trading Thursday after reports that CVS Health (NYSE:CVS) will not add the company’s new HIV prevention drug, Yeztugo, to its commercial plans for now.",
      "url": "https://finnhub.io/api/news?id=a116c6757a9c3aed11072c0198bee501deecfdc663cc8314e3efd6f55e4e2c3e"
    }
  },
  {
    "ts": null,
    "headline": "Warren Buffett's Modest Stake a Boost for UnitedHealth, But Work Left to be Done",
    "summary": "Berkshire Hathaway's (BRK.A, BRK.B) recent disclosure that it bought $1.6 billion of UnitedHealth Gr",
    "url": "https://finnhub.io/api/news?id=0dde0e0c14733dd4fe1015d8866701fc4f558f2ddbaeaef8d431d5ed86aeaeec",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755778152,
      "headline": "Warren Buffett's Modest Stake a Boost for UnitedHealth, But Work Left to be Done",
      "id": 136467453,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "Berkshire Hathaway's (BRK.A, BRK.B) recent disclosure that it bought $1.6 billion of UnitedHealth Gr",
      "url": "https://finnhub.io/api/news?id=0dde0e0c14733dd4fe1015d8866701fc4f558f2ddbaeaef8d431d5ed86aeaeec"
    }
  },
  {
    "ts": null,
    "headline": "CVS Health Stock Runs Hot Once Again, Hitting A New Buy Point",
    "summary": "CVS Health stock offers an above-average dividend yield for investors seeking income and it's run up to a new buy point.",
    "url": "https://finnhub.io/api/news?id=8eac78ca19ca1997c28d5b3bf4fed8a22e7e5d7268361fc04bf3412e848965f0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755777609,
      "headline": "CVS Health Stock Runs Hot Once Again, Hitting A New Buy Point",
      "id": 136467657,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "CVS Health stock offers an above-average dividend yield for investors seeking income and it's run up to a new buy point.",
      "url": "https://finnhub.io/api/news?id=8eac78ca19ca1997c28d5b3bf4fed8a22e7e5d7268361fc04bf3412e848965f0"
    }
  },
  {
    "ts": null,
    "headline": "Market Chatter: CVS Health Won't Cover Gilead's New HIV Prevention Drug Yet",
    "summary": "CVS Health (CVS) has decided not to include Gilead Sciences' (GILD) new HIV prevention drug, Yeztugo",
    "url": "https://finnhub.io/api/news?id=e63848e550ef812bca0552da187fba5b54b7291fa7137f25c22ab856146c21e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755772465,
      "headline": "Market Chatter: CVS Health Won't Cover Gilead's New HIV Prevention Drug Yet",
      "id": 136467660,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "CVS Health (CVS) has decided not to include Gilead Sciences' (GILD) new HIV prevention drug, Yeztugo",
      "url": "https://finnhub.io/api/news?id=e63848e550ef812bca0552da187fba5b54b7291fa7137f25c22ab856146c21e4"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Believes “TE Connectivity is an Excellent Company”",
    "summary": "TE Connectivity plc (NYSE:TEL) is one of the stocks Jim Cramer talked about. During the lightning round, a caller asked for Cramer’s opinion on the company, and he said: “I think TE Connectivity is an excellent company. I do like the Internet of Things. I think it’s even doing better than Analog Devices, to tell […]",
    "url": "https://finnhub.io/api/news?id=4916545b0c14db8f344e8c15908f0e07a3b24234ce933abe89784eadc6418517",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755747431,
      "headline": "Jim Cramer Believes “TE Connectivity is an Excellent Company”",
      "id": 136450569,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "TE Connectivity plc (NYSE:TEL) is one of the stocks Jim Cramer talked about. During the lightning round, a caller asked for Cramer’s opinion on the company, and he said: “I think TE Connectivity is an excellent company. I do like the Internet of Things. I think it’s even doing better than Analog Devices, to tell […]",
      "url": "https://finnhub.io/api/news?id=4916545b0c14db8f344e8c15908f0e07a3b24234ce933abe89784eadc6418517"
    }
  }
]